Lucid Diligence Brief: Syremis Therapeutics launches with $165M Series A in schizophrenia
Lucid Diligence Brief: Syremis Therapeutics launches with $165M Series A in…
Lucid Diligence Brief: BioNTech completes acquisition of CureVac
Lucid Diligence Brief: BioNTech completes acquisition of CureVac Professional…
Lucid Diligence Brief: Harbour BioMed and BMS collaboration on next-gen multi-specific antibodies
Lucid Diligence Brief: Harbour BioMed and BMS collaboration on next-gen…
Lucid Diligence Brief: Sanofi and ADEL sign global licensing deal in Alzheimer's
Lucid Diligence Brief: Sanofi and ADEL sign global licensing deal in…
Lucid Diligence Brief: Chai Discovery $130M Series B
Lucid Diligence Brief: Chai Discovery $130M Series B Professional audiences…
Lucid Diligence Brief: Impulse Dynamics $158m financing
Lucid Diligence Brief: Impulse Dynamics $158m financing Professional audiences…
Lucid Diligence Brief: Prolynx $70m Series A for long-acting obesity candidates
Lucid Diligence Brief: Prolynx $70m Series A for long-acting obesity……
Lucid Diligence Brief: Insilico-TaiGen CKD anemia licensing deal
Lucid Diligence Brief: Insilico-TaiGen CKD anemia licensing deal Professional…
Lucid Diligence Brief: Pfizer YaoPharma oral GLP-1 deal
Lucid Diligence Brief: Pfizer YaoPharma oral GLP-1 deal Professional audiences…
Lucid Diligence Brief: D3 Bio $108M Series B
Lucid Diligence Brief: D3 Bio $108M Series B Professional audiences only. Not…
Lucid Diligence Brief: Relation and Novartis atopic disease discovery alliance
Lucid Diligence Brief: Relation and Novartis atopic disease discovery alliance…
Lucid Diligence Brief: EpilepsyGTx $33m Series A
Lucid Diligence Brief: EpilepsyGTx $33m Series A Professional audiences only.…